Participants Needed for “Chemo Brain” Study

Minnesota Oncology and Virginia Piper Cancer Institute in Minneapolis are seeking participants for a study aiming to try to better understand, prevent and improve "chemo brain." (What is chemo brain?)

They will begin enrolling subjects on Monday, February 22 in the new study, called Focus Forward Cognitive PreHab.

To be considered for the study, patients must meet the following criteria:

  • Have been diagnosed with breast cancer or ovarian cancer, which represents a first cancer diagnosis and not a recurrence
  • Are scheduled to receive 1 of the following chemotherapy regimens for breast or ovarian cancer:
    • Taxotere and cyclophosphamide (Cytoxan) (TC)
    • Doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC)
    • Adriamycin and cyclophosphamide (Cytoxan) followed by Taxol (AC-T)
    • Taxotere, Carboplatin, Herceptin (TCH)
    • Paclitaxel and Carboplatin (6 cycles)
  • Be at least 18 years of age
  • Speak English
  • Be able to see and hear (with or without correction/hearing device)

Exclusion criteria:

  • Untreated/unstable psychiatric disorder
  • Known cognitive deficits from other conditions, including metastases to brain

To find out more about this study or apply to be a participant, contact Karen Swenson, PhD, RN (612-863-5658) or Mary Radomski, PhD, OTR/L (612-863-3291).




Recent Posts

November 30, 2022

Your healthcare provider may recommend additional screening to monitor your small lung nodule and watch for growth over time.

November 23, 2022

Lung cancer is the second most common type of cancer and the leading cause of cancer death in the U.S. Studies show that lung cancer screening reduces the risk of dying from the disease.

November 16, 2022

The American Cancer Society has hosted the Great American Smokeout on the third Thursday of November for more than 40 years.